^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CXCL13 (Chemokine (C-X-C motif) ligand 13)

    i
    Other names: CXCL13, ANGIE, ANGIE2, BCA-1, BLC, BLR1L, SCYB13, Chemokine (C-X-C motif) ligand 13
    3d
    KPT-8602 combined with IFN-γ released ZBP1-PANoptosome to inhibit the progression of primary central nervous system lymphoma. (PubMed, Exp Cell Res)
    The combination of KPT-8602 and IFN-γ can activate the pan-apoptotic pathway by upregulating ZBP1, thereby effectively inhibiting the growth of PCNSL. This study presented a promising new combination treatment strategy for PCNSL.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • IL18 (Interleukin 18) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • IL1B (Interleukin 1, beta)
    |
    eltanexor (KPT-8602)
    11d
    Tumor microenvironment-guided targeted and immunotherapy in anaplastic thyroid cancer: a literature review from preclinical models to clinical translation. (PubMed, Transl Cancer Res)
    This review provides clinicians with decision-making frameworks for TME-based treatment selection and identifies future research directions. Future directions include TME-stratified trials, biomarker standardization, and development of streamlined treatment algorithms to translate these advances into routine practice.
    Preclinical • Review • Journal • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    BRAF mutation
    12d
    Clinicopathological Characteristics and Prognostic Factors in Angioimmunoblastic T-cell Lymphoma: a Retrospective Analysis. (PubMed, Clin Lab)
    This study highlights the aggressive nature of AITL and identifies several readily accessible laboratory parameters as important prognostic factors. The protective effect of PD-1 positivity on survival outcomes warrants further investigation. While CHOP/CHOPE remains the standard treatment, the addition of novel targeted therapies shows promise for improving patient outcomes in this challenging lymphoma subtype.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • B2M (Beta-2-microglobulin) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    14d
    CD4+CXCL13+ exhausted T cells drive immune microenvironment divergence in synchronous double primary lung adenocarcinoma with different degrees of invasiveness. (PubMed, Transl Lung Cancer Res)
    This study found significant immune heterogeneity between sDPLA lesions with different degrees of invasiveness and identified CD4+ Tex CXCL13 cells as key drivers of tumor immune progression. Our findings provide new insights into early immune evolution and may inform precision immunotherapy strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    18d
    Inflammatory profile associated with hyperglycemia in children with type 1 diabetes. (PubMed, J Diabetes Complications)
    A broad range of inflammatory mediators are correlated with HbA1c in children with T1D. These inflammatory changes precede development of T1D complications, suggesting that possible pathophysiologic involvement should be investigated.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • MMP2 (Matrix metallopeptidase 2) • CCL2 (Chemokine (C-C motif) ligand 2) • IL18 (Interleukin 18) • CCL8 (C-C Motif Chemokine Ligand 8) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • CCL27 (C-C Motif Chemokine Ligand 27) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • IL13 (Interleukin 13) • IL21 (Interleukin 21) • IL4 (Interleukin 4) • MMP1 (Matrix metallopeptidase 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • IL33 (Interleukin 33) • LIF (LIF Interleukin 6 Family Cytokine)
    23d
    The role of sleep deprivation in prostate cancer and a preliminary exploration of its mechanisms. (PubMed, Pathol Res Pract)
    In summary, our findings suggest that sleep deprivation may accelerate prostate cancer progression by activating the CXCL13/CXCR5/JNK signaling axis. These results provide preliminary insights into a potential therapeutic direction.
    Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
    27d
    A proimmunotoxin nanodrug targeting AIDS-associated non-Hodgkin lymphoma. (PubMed, J Control Release)
    Importantly, n(ch128.1Av/b-SO6)-CXCL13 demonstrated antitumor efficacy in an AIDS-associated NHL xenograft mouse model. Taken together, our results suggest that n(ch128.1Av/b-SO6)-CXCL13, or similar proimmunotoxin strategies, represents a promising therapeutic avenue for AIDS-NHL and potentially other malignancies.
    Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • MMP2 (Matrix metallopeptidase 2) • TFRC
    28d
    C-X-C motif chemokine ligand 13 suppresses osteoclast differentiation via interference with RANKL-RANK interaction. (PubMed, Front Immunol)
    Mechanistically, CXCL13 attenuated MAPK and NF-κB activation and blocked p65 nuclear translocation in a CXCR5-independent manner by competitively interfering with RANKL-RANK binding and downstream RANK-TRAF6 signaling. These findings identify CXCL13 as a novel suppressor of osteoclastogenesis by interfering with RANKL-RANK signaling, unveiling an unrecognized regulatory role in osteoclast biology and suggesting potential therapeutic relevance for bone loss disorders.
    Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • CASP3 (Caspase 3) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • TRAF6 (TNF Receptor Associated Factor 6)
    1m
    A pleura-based follicular dendritic cell sarcoma with epithelioid morphology and aberrant expression of cytokeratins. (PubMed, J Hematop)
    FDCS is a rare neoplasm with variable morphologic and staining patterns. To the best of our knowledge, this is the first reported instance of pleura-based FDCS with epithelioid morphology and aberrant expression of cytokeratins. Diagnosis of such cases can be challenging, which has to be separated from the morphologic mimicries, particularly carcinoma and mesothelioma.
    Journal
    |
    RB1 (RB Transcriptional Corepressor 1) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CLU (Clusterin) • CR1 (Complement C3b/C4b Receptor 1) • FCER2 (Fc Fragment Of IgE Receptor II)
    1m
    Prognostic Value of Lymphoid Infiltration and Aggregation in Cervical Cancer. (PubMed, Cancers (Basel))
    Validation in The Cancer Genome Atlas (TCGA) cohort illustrated similar trends in survival. Collectively, this work demonstrates the prognostic significance of immune infiltration and eventual TLS induction in early cervical cancer and presents potential future therapeutic targets.
    Journal
    |
    CD8 (cluster of differentiation 8) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    2ms
    High expression of IQGAP3 promotes the infiltration of M0 macrophages into the TME, resulting in a poor prognosis for gastric cancer patients. (PubMed, Gastroenterol Rep (Oxf))
    IQGAP3 is a potential pro-carcinogenic factor in GC. IQGAP3 promotes the expression and secretion of CXCL13 via the ERK1/2 and STAT3 pathways, thereby causing M0 macrophages to infiltrate the TME.
    Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13)
    2ms
    The Predictive Value of Neutrophil Extracellular Trap-Related Risk Score in Prognosis and Tertiary Lymphoid Structure Features of Lung Adenocarcinoma Patients. (PubMed, J Leukoc Biol)
    Functional enrichment and immune infiltration analyses revealed that NETs-high tumors were associated with suppressive immune phenotypes, metabolic reprogramming, and impaired lymphoid chemokine expression (e.g., CCL19, CXCL13). Our findings suggest that NETs not only predict poor prognosis in LUAD but may also impair TLS maturation and local antitumor immunity, highlighting their potential as therapeutic targets.
    Journal
    |
    BCL6 (B-cell CLL/lymphoma 6) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CCL19 (C-C Motif Chemokine Ligand 19) • MPO (Myeloperoxidase)